HIVE Blockchain Technologies (CVE:HIV – Get Free Report) was upgraded by analysts at Keefe, Bruyette & Woods to a “moderate buy” rating in a report issued on Wednesday,Zacks.com reports.
HIV has been the subject of a number of other research reports. Cantor Fitzgerald raised shares of HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Tuesday, October 29th. Northland Capmk upgraded HIVE Blockchain Technologies to a “strong-buy” rating in a report on Thursday, September 19th. Finally, Roth Capital raised HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Wednesday, December 18th. Four analysts have rated the stock with a strong buy rating, According to data from MarketBeat, the stock currently has an average rating of “Strong Buy”.
Check Out Our Latest Stock Report on HIVE Blockchain Technologies
HIVE Blockchain Technologies Price Performance
Read More
- Five stocks we like better than HIVE Blockchain Technologies
- 3 REITs to Buy and Hold for the Long Term
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- What is a Death Cross in Stocks?
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- ETF Screener: Uses and Step-by-Step Guide
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
